# A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

> **NCT02468661** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 23 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** INC280 single agent
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT02468661
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-23
- **Primary completion:** 2017-11-15
- **Final completion:** 2018-12-05
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Major challenge for enrollment of participants.
- **Last updated:** 2020-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02468661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02468661, "A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02468661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*